NCT03595579View on ClinicalTrials.gov

Assessing Symptomatic Clinical Episodes in Depression

PHASE2CompletedINTERVENTIONAL
Enrollment

97

Participants

Timeline

Start Date

May 30, 2018

Primary Completion Date

January 7, 2019

Study Completion Date

January 7, 2019

Conditions
Major Depressive Disorder
Interventions
DRUG

AXS-05

AXS-05 taken twice daily for 6 weeks.

DRUG

Bupropion

Bupropion taken twice daily for 6 weeks.

Trial Locations (4)

32256

Clinical Research Site, Jacksonville

32801

Clinical Research Site, Orlando

90210

Clinical Research Site, Beverly Hills

98007

Clinical Research Site, Bellevue

Sponsors
All Listed Sponsors
lead

Axsome Therapeutics, Inc.

INDUSTRY

NCT03595579 - Assessing Symptomatic Clinical Episodes in Depression | Biotech Hunter | Biotech Hunter